|
1
|
Jessup M, Abraham WT, Casey DE, Feldman
AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS,
Silver MA, Stevenson LW and Yancy CW: 2009 focused update: ACCF/AHA
guidelines for the diagnosis and management of heart failure in
adults: a report of the American College of Cardiology
Foundation/American Heart Association. Task Force on Practice
Guidelines: developed in collaboration with the International
Society for Heart and Lung Transplantation. Circulation.
119:1977–2016. 2009.
|
|
2
|
Dickstein K, Cohen-Solal A, Filippatos G,
McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van
Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M,
Priori SG and Swedberg K; ESC Committee for Practice Guidelines
(CPG). ESC guidelines for the diagnosis and treatment of acute and
chronic heart failure 2008: the Task Force for the Diagnosis and
Treatment of Acute and Chronic Heart failure 2008 of the European
Society of Cardiology. Developed in collaboration with the Heart
Failure Association of the ESC (HFA) and endorsed by the European
Society of Intensive Care Medicine (ESICM). Eur Heart J.
29:2388–2442. 2008.
|
|
3
|
Wohlschlaeger J, Sixt SU, Stoeppler T,
Schmitz KJ, Levkau B, Tsagakis K, Vahlhaus C, Schmid C, Peters J,
Schmid KW, Milting H and Baba HA: Ventricular unloading is
associated with increased 20s proteasome protein expression in the
myocardium. J Heart Lung Transplant. 29:125–132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drews O, Tsukamoto O, Liem D, Streicher J,
Wang Y and Ping P: Differential regulation of proteasome function
in isoproterenol-induced cardiac hypertrophy. Circ Res.
107:1094–1101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stansfield WE, Tang RH, Moss NC, Baldwin
AS, Willis MS and Selzman CH: Proteasome inhibition promotes
regression of left ventricular hypertrophy. Am J Physiol Heart Circ
Physiol. 294:H645–H650. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hedhli N, Lizano P, Hong C, Fritzky LF,
Dhar SK, Liu H, Tian Y, Gao S, Madura K, Vatner SF and Depre C:
Proteasome inhibition decreases cardiac remodeling after initiation
of pressure overload. Am J Physiol Heart Circ Physiol.
295:H1385–H1393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Probstfield JL and O’Brien KD: Progression
of cardiovascular damage: the role of renin-angiotensin system
blockade. Am J Cardiol. 105:10A–20A. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto E, Kataoka K, Shintaku H,
Yamashita T, Tokutomi Y, Dong YF, Matsuba S, Ichijo H, Ogawa H and
Kim-Mitsuyama S: Novel mechanism and role of angiotensin II induced
vascular endothelial injury in hypertensive diastolic heart
failure. Arterioscler Thromb Vasc Biol. 27:2569–2575. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamamoto E, Kataoka K, Yamashita T,
Tokutomi Y, Dong YF, Matsuba S, Ogawa H and Kim-Mitsuyama S: Role
of xanthine oxidoreductase in the reversal of diastolic heart
failure by candesartan in the salt-sensitive hypertensive rat.
Hypertension. 50:657–662. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gervais M, Fornes P, Richer C, Nisato D
and Giudicelli JF: Effects of angiotensin II AT1-receptor blockade
on coronary dynamics, function, and structure in postischemic heart
failure in rats. J Cardiovasc Pharmacol. 36:329–337. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Richer C, Fornes P, Cazaubon C, Domergue
V, Nisato D and Giudicelli JF: Effects of long-term angiotensin II
AT1 receptor blockade on survival, hemodynamics and cardiac
remodeling in chronic heart failure in rats. Cardiovasc Res.
41:100–108. 1999. View Article : Google Scholar
|
|
12
|
Whaley-Connell A, Habibi J, Cooper SA,
Demarco VG, Hayden MR, Stump CS, Link D, Ferrario CM and Sowers JR:
Effect of renin inhibition and AT1R blockade on myocardial
remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol
Metab. 295:E103–E109. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Forni V, Wuerzner G, Pruijm M and Burnier
M: Long-term use and tolerability of irbesartan for control of
hypertension. Integr Blood Press Control. 4:17–26. 2011.PubMed/NCBI
|
|
14
|
Richer C, Gervais M, Fornes P and
Giudicelli JF: Combined selective angiotensin II AT1-receptor
blockade and angiotensin I-converting enzyme inhibition on coronary
flow reserve in postischemic heart failure in rats. J Cardiovasc
Pharmacol. 34:772–781. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsutsui H, Matsushima S, Kinugawa S, Ide
T, Inoue N, Ohta Y, Yokota T, Hamaguchi S and Sunagawa K:
Angiotensin II type 1 receptor blocker attenuates myocardial
remodeling and preserves diastolic function in diabetic heart.
Hypertens Res. 30:439–449. 2007. View Article : Google Scholar
|
|
16
|
Zhang RY, Wang LF, Zhang L, Meng XN, Li SJ
and Wang WR: Effects of angiotensin converting enzyme inhibitor,
angiotensin II type I receptor blocker and their combination on
postinfarcted ventricular remodeling in rats. Chin Med J (Engl).
119:649–655. 2006.
|
|
17
|
Kim BH, Cho KI, Kim SM, Kim JY, Choi BG,
Kang JH, Jeon YK, Kim SS, Kim SJ, Kim YK and Kim IJ: Irbesartan
prevents myocardial remodeling in experimental thyrotoxic
cardiomyopathy. Endocr J. 59:919–929. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Biswas S, Ghoshal PK, Mandal SC and Mandal
N: Relation of anti- to pro-inflammatory cytokine ratios with acute
myocardial infarction. Korean J Intern Med. 25:44–50. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bradham WS, Bozkurt B, Gunasinghe H, Mann
D and Spinale FG: Tumor necrosis factor-alpha and myocardial
remodeling in progression of heart failure: a current perspective.
Cardiovasc Res. 53:822–830. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelly ML, Wang M, Crisostomo PR,
Abarbanell AM, Herrmann JL, Weil BR and Meldrum DR: TNF receptor 2,
not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac
protection following acute ischemia. Shock. 33:602–607. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Daniels MC, Keller RS and de Tombe PP:
Losartan prevents contractile dysfunction in rat myocardium after
left ventricular myocardial infarction. Am J Physiol Heart Circ
Physiol. 281:H2150–H2158. 2001.PubMed/NCBI
|
|
22
|
Gurlek A, Kilickap M, Dincer I, Dandachi
R, Tutkak H and Oral D: Effect of losartan on circulating TNFα
levels and left ventricular systolic performance in patients with
heart failure. J Cardiovasc Risk. 8:279–282. 2001.
|
|
23
|
Tsutamoto T, Wada A, Maeda K, Mabuchi N,
Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T and
Kinoshita M: Angiotensin II type 1 receptor antagonist decreases
plasma levels of tumor necrosis factor alpha, interleukin-6 and
soluble adhesion molecules in patients with chronic heart failure.
J Am Coll Cardiol. 35:714–721. 2000. View Article : Google Scholar
|
|
24
|
Sixt SU and Dahlmann B: Extracellular,
circulating proteasomes and ubiquitin - incidence and relevance.
Biochim Biophys Acta. 1782:817–823. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marfella R, Di Filippo C, Portoghese M,
Siniscalchi M, Martis S, Ferraraccio F, Guastafierro S, Nicoletti
G, Barbieri M, Coppola A, Rossi F, Paolisso G and D’Amico M: The
ubiquitin-proteasome system contributes to the inflammatory injury
in ischemic diabetic myocardium: the role of glycemic control.
Cardiovasc Pathol. 18:332–345. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van Hees HW, Li YP, Ottenheijm CA, Jin B,
Pigmans CJ, Linkels M, Dekhuijzen PN and Heunks LM: Proteasome
inhibition improves diaphragm function in congestive heart failure
rats. Am J Physiol Lung Cell Mol Physiol. 294:L1260–L1268.
2008.PubMed/NCBI
|
|
27
|
Barbieri M, Marfella R, Rizzo MR, Boccardi
V, Siniscalchi M, Schiattarella C, Siciliano S, Lemme P and
Paolisso G: The -8 UTR C/G polymorphism of PSMA6 gene is associated
with susceptibility to myocardial infarction in type 2 diabetic
patients. Atherosclerosis. 201:117–123. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Friehs I: Proteasome inhibition in
hypertrophied myocardium. Am J Physiol Heart Circ Physiol.
295:H1373–H1374. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Su H and Wang X: The ubiquitin-proteasome
system in cardiac proteinopathy: a quality control perspective.
Cardiovasc Res. 85:253–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
